ISPOR - Is Fda’s Breakthrough Therapy Designation A Game-Changing Trend For Patients And Payers?

Full Text

Is Fda’s Breakthrough Therapy Designation A Game-Changing Trend For Patients And Payers?

Abstract

Authors

S. Aggarwal H. Topaloglu

Back to Volume 17, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now